Conditions: HIV
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 3
Healthy volunteers: no

Brief summary:
The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one additional drug \[Lamivudine (3TC) 300 mg daily\] or 2 additional drugs \[Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily\].

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Atazanavir intervention 2: Ritonavir intervention 3: Lamivudine intervention 4: Tenofovir/Emtricitabine
Intervention descriptions: intervention 1: Capsule, oral, 300 mg, Once daily (QD), 96 weeks intervention 2: Tablets, oral, 100 mg, QD, 96 Weeks intervention 3: Tablet, oral, 300 mg, QD, 96 Weeks intervention 4: Tablets, oral, 300/200 mg, QD, 48 Weeks

Protocol document: